Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Disruptive Innovation in Dialysis and Medical Device Manufacturing

Disruptors come in many flavors and innovate countless industries. Healthcare is one space that welcomes technology disruption, where advancements in medical devices can improve the lives of many. Outset Medical is one such medical device manufacturer seeking to transform the dialysis experience. Marc Nash, VP of Manufacturing at Outset Medical, joined DisruptED’s Ron Stefanski…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from DisruptED on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Disruptors come in many flavors and innovate countless industries. Healthcare is one space that welcomes technology disruption, where advancements in medical devices can improve the lives of many. Outset Medical is one such medical device manufacturer seeking to transform the dialysis experience.

Marc Nash, VP of Manufacturing at Outset Medical, joined DisruptED’s Ron Stefanski to share his company’s exciting work to improve the dialysis process and experience. A dialysis patient must endure a cumbersome lifelong process that creates a burden for them and their family, not to mention the physical toll it carries on the body.

“We wanted to see how we could give patients back their life,” Nash said. “How could they take more control over what they could do? So, we created a product called Tablo, and we’re now in the home market.”

Making dialysis available in a patient’s home is a critical first step in that journey to give patients their freedom back. With a typical dialysis treatment taking five hours and up to three times a week, not traveling to a healthcare facility to get treatment can be a game-changer.

“Imagine if you wanted to do dialysis at 7 p.m. to 10 p.m. or 11 p.m., most clinics are not going to be open during these times,” Nash said. “Where if you’re in the comfort of your house, you can go to work, take care of the kids, and then go about your dialysis.”

Nash said it comes down to the people within Outset Medical to make strides in dialysis.

“When I hire within my organization, I’m looking for attitude. I want to see the people that have grit and determination. Most people are not going to come to my organization knowing dialysis; they’re going to come from either the Medtech space, aerospace, they’re going to come from automotive, or tech, and I’m going to have to teach them dialysis. That’s the easy part. What’s hard to teach is grit.”

DisruptED

Part of this channel

DisruptED

Education, workforce, and manufacturing futures with Ron J. Stefanski.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512